WSAVA - FECAVA CONGRESS LYON 1999

 

SAFETY AND EFFICACY OF A RECOMBINANT FELV VACCINE COMBINED WITH A LIVE FELINE CRP VACCINE

 

P. MÄHL, S. GUEGUEN and A. AUBERT

 

Vaccination against feline calicivirosis, rhinotracheitis and panleukopaenia (CRP) and against FeLV is often performed in cats via two separate injections. The possibility of combining these fractions presents two obvious advantages; it reduces the handling requirement of aggressive cats and also means less pain by reducing the number of injections. The efficacy of Feligen CRP (CRP vaccine, Virbac) and Leucogen (recombinant FeLV vaccine, Virbac) is well established when injected separately. This study was designed to determine the safety and efficacy of these vaccines when combined prior to injection in cats.

The safety study consisted of overdosed and repeated injections on ten SPF kittens. For the efficacy study, 48 SPF kittens were used. Ten kittens each received one dose of Leucogen at day 0 and day 21 (group 1), 13 kittens each received one dose of Feligen CRP re-suspended with diluent at day 0 and day 21 (group 2), 15 kittens each received one dose of Feligen CRP re-suspended with one dose of Leucogen at day 0 and day 21 (group 3) and 10 kittens remained unvaccinated as controls (group 4).

In kittens that received the CRP/Leucogen combination the serological responses to the calicivirus and to the rhinotracheitis virus were significantly better (respectively p=0.001 and p=0.003) than the reference serological responses in kittens given CRP alone. The serological response to the panleukopaenia virus was high in both vaccine groups. Both Leucogen and CRP/Leucogen gave highly significant protection against challenge compared to controls (respectively p=0.005 and p=0.002) and no significant difference was found between kittens vaccinated with either Leucogen or CRP/Leucogen.

The results indicate that combining Feligen CRP and Leucogen is safe and effective and can also provide a higher serological response against the calicivirus and rhinotracheitis components which may be due to an immunostimulating effect of the adjuvants contained in Leucogen.